Last reviewed · How we verify
HNC364 Injectable Suspension — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
HNC364 Injectable Suspension (HNC364 Injectable Suspension) — Guangzhou Henovcom Bioscience Co. Ltd..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| HNC364 Injectable Suspension TARGET | HNC364 Injectable Suspension | Guangzhou Henovcom Bioscience Co. Ltd. | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- HNC364 Injectable Suspension CI watch — RSS
- HNC364 Injectable Suspension CI watch — Atom
- HNC364 Injectable Suspension CI watch — JSON
- HNC364 Injectable Suspension alone — RSS
Cite this brief
Drug Landscape (2026). HNC364 Injectable Suspension — Competitive Intelligence Brief. https://druglandscape.com/ci/hnc364-injectable-suspension. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing